Roche and Eli Lilly received U.S. FDA clearance for Elecsys Phospho-Tau (217P) Plasma, a blood test intended to identify amyloid pathology associated with Alzheimer’s disease. The assay targets individuals 55 and older who present with signs, symptoms or complaints of cognitive decline. The clearance adds to the growing set of plasma biomarker tests used to support earlier identification of underlying Alzheimer’s biology. It also broadens the diagnostic toolkit beyond cerebrospinal fluid biomarkers and imaging. By bringing another blood-based marker into the U.S. market, the companies position their test for clinical workflows where clinicians need a scalable method to evaluate amyloid-associated disease.